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Treatment responseDysfunction of the frontal lobe is considered to be central to the pathology of schizophrenia. However, the
nature of these abnormalities is unclear, in particular whether they are affected by treatment. In an earlier
functional MRI study of our group we found dorsolateral prefrontal lobe (DLPFC) dysfunction to be present in
medication-naive ﬁrst-episode patients. In this follow-up study, we investigated whether treatment with
atypical antipsychotics had an effect on DLPFC functioning, and whether (change in) DLPFC functioning was
related to treatment response.
Twenty-three medication-naive, ﬁrst-episode male schizophrenia patients and 33 matched healthy controls
were scanned at baseline and were re-scanned after 10 weeks, while performing a modiﬁed Sternberg
working-memory task. We speciﬁcally investigated the effect of practice on brain activation, deﬁned as the
signal change between a novel and practiced working-memory task. After the baseline scan, patients were
treated with atypical antipsychotics. Based on their symptom change after ten weeks, patients were divided
into responders and non-responders
We found DLPFC function did not change after 10 weeks in healthy controls or in patients who received
treatment. However, while patients who responded to treatment did not differ from controls, non-responders
showed a reduced practice effect in the DLPFC that was present already at baseline, which did not change after
treatment. A reduced practice effect in the DLFPC at baseline was found to be predictive of poor treatment
response at 10 weeks.
These results suggest that prefrontal lobe dysfunction reﬂects a distinct neuropathological substrate in a
subgroup of treatment non-responsive schizophrenia patients.f Neuroscience, Department of
0.241, Heidelberglaan 100, P.O.
+31 88 7558180; fax: +31 88
van Veelen).
vier OA license. © 2011 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
From the ﬁrst description of the illness by Emil Kraepelin over a
century ago, abnormalities of the frontal lobe have been thought to be
central to the pathology of schizophrenia. Indeed, structural (Pantelis
et al., 2007; Ho et al., 2003; Job et al., 2005; Pantelis et al., 2005; Hazlett
et al., 2008; Hulshoff Pol and Kahn, 2008; Antonova et al., 2004; Gur et al.,
1998) as well as functional magnetic resonance imaging (MRI) studies
(Weinberger et al., 1992; Andreasen et al., 1992b; Yurgelun-Todd et al.,
1996; Buchsbaum et al., 1992; Ragland et al., 1998; Karlsgodt et al., 2007;
Jansma et al., 2001) report abnormalities of the frontal lobe. In a previous
functional MRI study, we found dorsolateral prefrontal lobe (DLPFC)
dysfunction to be present already in ﬁrst-episode patients who weremedication-naive (vanVeelenet al., 2010). Thiswas found tobe related to
the severity of negative symptoms and disorganization.
We now extend this study and investigate whether subsequent
treatment with atypical antipsychotics has an effect on DLPFC
functioning. As it is evident that not all patients respond to
antipsychotic treatment (Robinson et al., 2005; Leucht et al., 2007)
and that the outcome of the illness is heterogeneous (van Os and
Kapur, 2009), we also test if treatment response is related to DLPFC
functioning. For example, structural MRI studies have shown that
more pronounced progressive brain changes in the frontal lobes are
associated with poor outcome (Hulshoff Pol and Kahn, 2008;
Weinberger et al., 1992; Andreasen et al., 1992b; Yurgelun-Todd
et al., 1996). Furthermore, one may expect patients with impaired
prefrontal lobe function to show diminished response to antipsy-
chotic treatment since these drugs have been found to have limited
effects on improving negative symptoms (Buckley and Stahl, 2007;
Erhart et al., 2006; Alphs, 2006) and cognitive performance (Keefe,
2007; Goldberg et al., 2007), both having been related to prefrontal
lobe function.
Fig. 1. Schematic display of the modiﬁed Sternberg working memory task (Sternberg,
1966; Jansma et al., 2001; Ramsey et al., 2004; Jager et al., 2006; van Raalten et al., 2008;
van Veelen et al., 2010). Each task block starts with the presentation of a memory set
(here FGMPT) and is followed by ten probes, each presented 1 s apart. Five probes were
part of thememory set (target) and ﬁve were not (non-target). Subjects had to indicate,
by pressing a button, whether this letter was part of the memorized set. Prior to
scanning, subjects practiced the task for 20 min, using a predeﬁnedmemory set that did
not change throughout the practice session. During scanning, task blocks with the
practiced memory set (Practiced Task, PT) were semi-randomly mixed with task blocks
with a novel memory set (Novel Task, NT). In addition, a Control task (CT) was included
during which subjects had to press a button when the symbols ‘b N’ appeared. The
entire experiment lasted about 18 min and consisted of the pseudo-randomized
presentation of eight blocks (memory set and ten probes) for each condition (total 24
blocks) interleaved with resting periods. For the second scan-session, a new set of
letters was used for the PT. The focus of the current study was on the effect of practice,
i.e. the difference between activation during PT versus NT blocks.
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phrenia patients before and after an open ten week treatment trial
with (atypical) antipsychotic treatment, using a modiﬁed Sternberg
working memory task (Jansma et al., 2001; Ramsey et al., 2004; Jager
et al., 2006; van Raalten et al., 2008; van Veelen et al., 2010). Patients
are matched with healthy controls, and all subjects are scanned twice.
Based on their symptom change after 10 weeks of treatment, patients
are categorized as responder or non-responder. In this way, we can
examine whether treatment affects DLPFC function in patients and
whether dysfunction in this region is related to treatment response.
2. Materials and methods
2.1. Participants
All subjects were part of a larger cohort, described previously, in
which 30 medication-naive ﬁrst-episode patients and 36 matched
healthy controls participated (van Veelen et al., 2010). The diagnosis
of schizophrenia or schizophreniform disorder in patients was
assessed with the Structured Clinical Interview for DSM IV (First
et al., 1996) or The Comprehensive Assessment of Symptoms and
History (Andreasen et al., 1992a) and conﬁrmed after 6 months.
The Mini International Neuropsychiatric Interview (Sheehan et al.,
1998) was used to exclude controls with a history of psychiatric or
neurologic disorder, or with any ﬁrst degree relatives with a psychotic
disorder. Participants with a diagnosis of substance abuse within the
previous 3 months were excluded.
In the current study we obtained functional MRI data from 23
patients and 33 healthy controls, who were scanned at baseline prior
to treatment (see van Veelen et al., 2010) and after 10 weeks (10.1±
2.2 weeks). The seven patients who did not have a second scan did
not differ from those patients who were scanned at both time points
in demographic and clinical measures at baseline.
Patients were started on atypical antipsychotic treatment after the
baseline scan (van Veelen et al., 2010); the use of concomitant
antidepressant medication and mood stabilizers was prohibited. Prior
to each scan, symptom ratings were recorded using the Positive and
Negative Syndrome Scale (PANSS) (Kay et al., 1987). After 10 weeks of
treatment, patients were categorized as responder or non-responder
based on the change in total PANSS score. Treatment response was
deﬁned as a reduction of more than 30% in total PANSS score (Leucht
et al., 2005).
The study was approved by the Ethics Committee of the University
Medical Center of Utrecht. Written informed consent was obtained
from all subjects prior to participation in the study.
2.2. Working memory task
Subjects performed a modiﬁed Sternberg working memory task
with a practiced (PT) and a Novel (NT) memory set. Task design and
experimental procedure were identical to those described previously
(van Veelen et al., 2010) and are brieﬂy explained in Fig. 1.
2.3. Functional MRI data acquisition
For the image acquisition, a navigated echo 3D-PRESTO pulse
sequence (van Gelderen et al., 1995; Ramsey et al., 1998) was used, on
a 1.5-T Philips ACS-NT MRI scanner. The following parameter settings
were used: Echo time/Repetition time 35/24 ms, ﬂip angle 10.5°, Field
of view: 256×120×208 mm, data matrix 64×52, voxel size 4 mm
isotropic, 30 slices. A single run of 384 scans was acquired over a
period of 18 min. A reference image with the same speciﬁcations as
the functional scans, but with more anatomical contrast (ﬂip angle
30°) was also acquired to facilitate coregistration to the anatomical
image. Finally, an anatomical T1-weighted scan was acquired (voxel
size 1 mm isotropic).2.4. Treatment
Patients were treated with olanzapine (n=13, mean dose 15±
4.8 mg), risperidone (n=4, mean dose 4±1.4 mg), quetiapine
(n=3, mean dose 733±567 mg), or ziprasidone (n=3, mean dose
65±19.2 mg).
2.4.1. Data analysis: behavioral data
Reaction times (RT) of all correctly identiﬁed targets, as well as
accuracy (i.e. percentage correctly identiﬁed targets and non-targets)
were tested with a repeated-measures GLM analysis with time
(baseline, second scan-session) and task (NT, PT) as within-subject
and group (either patients and controls or responders and non-
responders) as between-subject factor.
2.4.2. Data analysis: imaging data
Data analysis and pre-processing was performed using SPM5
(Wellcome Trust Centre for Neuroimaging, London, http://www.ﬁl.
ion.ucl.ac.uk/spm). Preprocessing and ﬁrst-level statistical analyses
were performed as described previously (van Veelen et al., 2010). In
brief, preprocessing involved realignment for head motion correction,
coregistration of functional images to the anatomical image, spatial
normalization to the Montreal Neurological Institute template brain,
and spatial smoothing (8 mm FWHM) of functional images.
The functional data were then analyzed voxel-wise, using a
general linear model (GLM) including regressors modeling the onsets
and durations of the NT, PT and Control Task (CT) blocks as well as the
memory sets that were presented at the beginning of each taskblock.
These factors were convolved with a canonical hemodynamic
response function (Friston et al., 1995). To correct for head motion,
the six realignment parameters were included in the design matrix as
regressors of no interest. To correct for drifts in the signal, a high-pass
ﬁlter was applied to the data with a cut-off frequency of 0.003 Hz.
To test for the effects of practice (NT–PT) on brain activation, we
used Regions of Interest (ROIs) that included the Left Fusiform Gyrus
(LFG), Left and Right Superior Parietal Cortex (LSPC and RSPC),
Anterior Cingulate Gyrus (ACC) and the left Dorsolateral Prefrontal
Fig. 2. Regions of Interest (ROIs) determined in an independent sample in an earlier
study of our group, obtained from the Novel Task versus Control Task contrast (for
details, see Table 1). 1. left fusiform gyrus (LFG), 2. left dorsolateral prefrontal cortex
(DLPFC), 3. left superior parietal cortex (LSPC), 4. right superior parietal cortex (RSPC),
5. anterior cingulate cortex (ACC). The numbers in the slices correspond to MNI
z-coordinates (Collins et al., 1994). Threshold for signiﬁcance corresponded to 0.05
Bonferroni-corrected, with a minimum cluster size of 10 voxels. Slices are in radiological
orientation (left side is right hemisphere and vice versa).
Table 2
Demographic and clinical characteristics of participants at baseline.
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determined in an independent sample performing the same task (van
Raalten et al., 2008), to avoid biasing of our results via data selection
as described by Kriegeskorte et al. (2009) and were identical to the
regions used in our previous report on the baseline scan (van Veelen
et al., 2010).
For each subject, the average level of brain activation (i.e. b-value)
over all voxels per ROI was obtained for NT and PT. These data were
entered into a repeated-measures GLM analysis with time (baseline,
second scan-session), task (NT, PT) and ROI as within-subject factors
and group (patients, controls) as between-subject factor. In this way,
the effects of illness and the effect of treatment and/or retesting could
be tested. A similar analysis was performed for responders and non-
responders. Furthermore, to determine whether frontal lobe activa-
tion at baseline was predictive of clinical outcome after 10 weeks, a
regression analysis was performed with PANSS improvement as
dependent variable and the practice effect on brain activation in the
DLPFC as independent variable.
3. Results
3.1. Participants
Patients were moderately ill with a mean total PANSS score of 75.0
(±11.4) and had a mean duration of illness of 4.9 (±4.4) months at
inclusion (see Table 2). After 10 weeks of treatment, 11 patients were
classiﬁed as responder and 12 as non-responder. Responders and
non-responders did not differ in socio-demographic features or in the
PANSS scores at the baseline scan (see Table 3). Two patients used
benzodiazepines (b20 mg oxazepam) at baseline scanning, one
responder, one non-responder.
3.2. Behavioral data
3.2.1. Patients versus controls
Data are presented in Table 4. Patients were slower than controls
(main effect of group: F(1,45)=6.10, p=0.02). However, the
improvement in response speed with practice (PT versus NT) was
equal for patients and controls (group by task interaction: F(1,45)=
0.26, p=0.61) and was not affected by time (main effect of time:
F(1,45)=0.01, p=0.93), group by time interaction: F(1,45)=1.19,
p=0.28, group by task by time interaction: F(1,45)=1.99, p=0.17.
Patients and healthy controls did not differ in accuracy (effect of
group: F(1,45)=2.43, p=0.13). More importantly, the improvement
in accuracy with practice (main effect of task: F(1,45)=43.21,
pb0.001)was equal in patients and controls (group by task interaction:
F(1,45)=1.73, p=0.20), and was not affected by time (main effect of
time: F(1,45)=0.96, p=0.33, group by time interaction: F(1,45)=
1.18, p=0.29, group by task by time interaction: F(1,45)=0.37,
p=0.55).Table 1
Regions of interest.
Region Brodmann
area
Number of
voxels
X Y Z Maximum
t-value
Left fusiform gyrus 37 14 45 −59 −11 10.53
Left dorsolateral
prefrontal cortex
9/46 193 46 11 29 14.36
Left superior parietal
cortex
7 133 33 −56 41 10.31
Right superior parietal
cortex
7 56 −32 −60 42 8.77
Anterior cingulate cortex 6/24 57 4 23 53 18.52
Regions of interest identiﬁed in the group t-map of the modiﬁed Sternberg task (NT
versus CT contrast, for the patients and controls combined) (van Raalten et al., 2008).
TheMNI-coordinates of the voxel with the highest statistical value (group-map t-score)
within each region are listed under X, Y and Z (Collins et al., 1994).3.2.2. Responders versus non-responders
Data are presented in Table 5. The improvement of response speed
with practice (main effect of task: F(1,13)=19.34, p=0.001) did not
differ between the patient groups (group by task interaction: F(1,13)=
0.05, p=0.82) and was not affected by time (main effect of time:
F(1,13)=0.37, p=0.55, group by time interaction: F(1,13)=0.05,
p=0.82, group by task by time interaction: F(1,13)=0.18, p=0.68).
There was no difference between responders and non-responders
in overall RT (effect of group: F(1,13)=, p=0.52). The improvement
in accuracy with practice (main effect of task: F(1,13)=11.44,
p=0.005) did not differ between the groups (group by task
interaction: F(1,13)=0.54, p=0.48) and was not affected by time
(main effect of time: F(1,13)=0.50, p=0.50, group by time interac-
tion: F(1,13)=1.12, p=0.31, group by task by time interaction:
F(1,13)=0.16, p=0.70). There was no difference between responders
and non-responders in overall accuracy (effect of group: F(1,13)=2.35,
p=0.15).
3.3. Neuroimaging data
3.3.1. Patients versus controls
Activation levels for NT and PT were not signiﬁcantly different
between the groups (main effect of group: F(1,54)=0.17, p=0.70).
Across all ROIs, activation for NT was signiﬁcantly higher than for PT
(main effect of task F(1,54)=290.51, pb0.001). This differed between
the groups (group by task interaction: F(1,54)=6.57, p=0.01),Characteristics Healthy
controls (n=33)
Mean (±SD)
Patients
(n=23)
Mean (±SD)
p
Mean age in years 24.5 (±4.7) 25.3 (±4.6) 0.53
Mean parental education in years 12.9 (±3.2) 12.6 (±2.6) 0.78
Mean subject education in years 13.2 (±2.4) 11.2 (±2.7) 0.006
EHI 0.97 (±0.1) 0.93 (±0.1) 0.15
Illness duration (months) 4.9 (±4.3)
Diagnose schizophreniform disorder 11
Diagnose schizophrenia 12
PANSS total 75.0 (±11.4)
PANSS positive 21.7 (±4.0)
PANSS negative 16.4 (±5.1)
PANSS general 37.0 (±5.9)
Note. Values enclosed in parentheses represent standard deviation (SD). PANSS:
Positive and Negative Syndrome Scale (Kay et al., 1987), EHI: Edinburgh Handedness
Index (Oldﬁeld, 1971). (Signiﬁcance of differences is calculated using t-tests). All
participants were male.
Table 3
Demographic and clinical characteristics of responders and non-responders at baseline.
Characteristics Responders
(n=11)
Mean (±SD)
Non-responders
(n=12)
Mean (±SD)
p
Mean age in years 23.9 (±4.1) 26.5 (±4.8) 0.11
Mean parental education in years 13.2 (±2.3) 11.9 (±2.9) 0.50
Mean subject education in years 11.5 (±2.6) 10.8 (±2.9) 0.60
EHI 0.98 (±0.1) 0.88 (±0.2) 0.09
Illness duration 5.3 (±5.2) 4.5 (±3.4) 0.80
PANSS total 71.1 (±12.2) 78.6 (±9.9) 0.12
TOTAL positive 20.4 (±4.8) 22.9 (±2.9) 0.17
TOTAL negative 15.9 (±5.5) 16.8 (±5.0) 0.61
TOTAL general 34.8 (±5.1) 38.9 (±6.2) 0.12
Haldol doses equivalent mg/day
(at time of second scan-session)
5.2 (±2.1) 6.3 (±1.7) 0.21
Note. Values enclosed in parentheses represent standard deviation (SD). PANSS: Positive
and Negative Syndrome Scale (Kay et al., 1987), CGI: EHI: Edinburgh Handedness Index
(Oldﬁeld, 1971) (Signiﬁcance of differences is calculated using t-tests). Responders had a
reduction of more than 30% on total PANSS (after subtracting the minimum score of 30 of
the total PANSS) after 10 weeks (Leucht et al., 2005).
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compared to controls. In addition, the group by task by ROI interaction
was signiﬁcant (F(4,51)=3.57, p=0.01), suggesting that thedifference
in the effect of practice on brain activation between the groups was
different across ROIs. Consistent with our previous report which
included these patients, post-hoc t-tests revealed that the difference
betweenpatients and controlswas signiﬁcant in the left DLPFC (t(54)=
−2.83, p=0.007) and bilateral SPC cortex (left: t(54)=−2.34,
p=0.23, right: t(54)=−3.13, p=0.003), with patients showing a
smaller reduction in activation with practice (see Fig. 3A).
Therewasnoeffect of timeonbrain activation levels (F(1,54)=2.51,
p=0.12), nor was any interaction with time signiﬁcant, indicating that
treatment in patients had no additional effect over test–retest effects in
controls in any of the ROIs (time by task interaction: F(1,54)=1.23,
p=0.27), time by group interaction: F(1,54)=2.19, p=0.15, time by
task by group interaction (F(1,54)=0.24, p=0.62), time by task by
group by ROI interaction (F(4,51)=1.53, p=0.21).
3.3.2. Responders versus non-responders
Activation levels for NT and PT were not signiﬁcantly different
between the groups (main effect of group: F(1,21)=1.02, p=0.33).
Across all ROIs, activation for NT was signiﬁcantly higher than for PT
(main effect of task: F(1,21)=136.46, pb0.001), but this differed
between the groups (group by task interaction: F(1,21)=6.42,
p=0.02), indicating a decrease in activation with practice for
responders but not for non-responders. Furthermore, the group by
task by ROI interaction was signiﬁcant (F(1,21)=3.40, p=0.03),
suggesting that the difference in the effect of practice on brain
activation between the groups was different across ROIs. Post-hoc
t-tests revealed that the difference between responders and non-
responders was signiﬁcant in the left DLPFC (t(21)=3.56, p=0.002),Table 4
Behavioral measures patients and healthy controls.
Novel task
SZ n=23
Mean (±SD)
HC n=33
Behavioral measures baseline scan
Reaction times (ms) 822 (±25) 746 (±16)
Accuracy (percentage) 85 (±2) 93 (±1)
Behavioral measures second scan
Reaction times (ms) 800 (±23) 755 (±14)
Accuracy (percentage) 89 (±3) 92 (±2)
Performance data, in means (±SD).
Effect of practice=improvement after practice, SD=standard deviation, SZ=schizophreniand right SPC (t(21)=2.11, p=0.05) with non-responders showing a
smaller decrease in activation with practice. Importantly, the reduced
effect of practice on brain activation in non-responders was already
evident at the baseline scan session when compared to responders
(t(21)=2.35, p=0.03), as well as healthy controls (t(43)=3.48,
p=0.001) in the left DLPFC, but not in any other ROI. Responders and
controls did not differ in the left DLPFC (t(42)=−0.31, p=0.76) or
any other ROI (see Fig. 3B).
Similar to the analysis of patients versus controls, there was no
effect of time on brain activation levels (F(1,21)=0.01, p=0.96), nor
did any interaction with time reach signiﬁcance, indicating that
treatment response itself had no additional effect over test–retest
effects in any of the ROIs (time by group interaction: F(1,21)=0.07,
p=0.80, time by task interaction: F(1,21)=0.16, p=0.70, time by
task by group: F(1,21)=0.59, p=0.45, time by task by group by ROI
interaction: F(4,18)=1.81, p=0.14).
To assess the predictive value of the baseline scan for clinical
outcome we conducted a regression analysis with activity reduction
with practice in the ﬁve ROIs as independent variables, and reduction
in PANSS scores as dependent variable. This analysis showed that the
effect of practice on brain activation in the working memory network
at the baseline scan session was predictive of clinical outcome at ten
weeks (F(5,17)=3.93, p=0.02) with smaller clinical improvement
associated with a smaller pretreatment practice effect on brain
activation. This was caused by the effect in the left DLPFC, which
had the only regression coefﬁcient differing signiﬁcantly from zero
(t(22)=3.24, p=0.005; see Fig. 3C). When excluding the patient
that had a substantial increase of symptoms over time, this effect
remained signiﬁcant (t(21)=2.35, p=0.03). Running the other
previous analyseswithout this patient did not change signiﬁcances of
the results.
4. Discussion
This study examined whether prefrontal lobe dysfunction in
medication-naive schizophrenia is altered by antipsychotic treatment,
and whether prefrontal lobe dysfunction is related to treatment
response. Medication-naive ﬁrst-episode schizophrenia patients were
scanned prior to and after 10 weeks of antipsychotic treatment.
Results were compared to those of closely matched healthy subjects.
While being scanned subjects performed a modiﬁed Sternberg
workingmemory task with a practiced and a novel memory set to test
for the effect of practice on brain activation.
As we have shown in our previous paper (van Veelen et al., 2010),
function of the left dorsolateral prefrontal cortex (DLPFC) was
signiﬁcantly impaired in medication-naive schizophrenia patients:
while practice was associated with a reduction in brain activation in
healthy controls, this decrease in activation did not occur in the
patients. In the current follow-up study, we now show that
antipsychotic treatment does not change this dysfunction of the
DLPFC.Practiced task Effect of practice
SZ HC SZ HC
752 (±25) 683 (±18) 70 (±10) 63 (±10)
94 (±02) 98 (±0.2) 9 (±1) 5 (±1)
769 (±28) 697 (± 16) 30 (±19) 58 (±10)
97 (±0.8) 95 (±1.8) 8 (±3) 3 (±2)
a, HC=healthy controls.
Table 5
Behavioral measures responders and nonresponders.
Novel task Practiced task Effect of practice
Resp n=11
Mean (±SD)
Nonresp n=12 Resp Nonresp Resp Nonresp
Behavioral measures baseline scan
Reaction times (ms) 788 (±28) 852 (±38) 729 (±31) 772 (±40) 59 (±12) 80 (±16)
Accuracy (percentage) 87 (±3) 82 (±3) 97 (±0.4) 92 (±1.6) 10(±2) 10 (±3)
Behavioral measures second scan
Reaction times (ms) 784 (±26) 810 (±34) 740 (±30) 787 (± 41) 44 (±24) 23 (±27)
Accuracy (percentage) 90 (±3) 87 (±4) 98 (±1.7) 97 (±0.8) 8 (±2) 10 (±4)
Performance data, in means (±SD).
Effect of practice=improvement after practice, SD=standard deviation, resp=responders, schizophrenia patients responding to treatment, nonresp: nonresponders,
schizophrenia patients not responding to treatment.
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far from uniform: the abnormal left DLPFC function was almost
entirely accounted for by the subgroup of patients who failed to
respond to antipsychotic treatment. In contrast, in patients who
responded to treatment left DLPFC activation levels were not different
from that of the healthy subjects. Moreover, reduced effect of practice
in the DLPFC at baseline was predictive of poor clinical outcome at
10 weeks. Importantly, while DLPFC activity differentiated responders
from non-responders, these groups could not be discriminated by
their test performance, suggesting that the difference in functional
brain activity is not merely an artifact of poor performance in patients
non-responsive to treatment. Moreover, differences could not be
explained by symptom severity, as responders and non-responders
did not differ on total PANSS or PANSS sub-scores at the baseline scan.
Taken together, these ﬁndings suggest that prefrontal lobe dysfunc-
tion is a stable trait characteristic of treatment non-responsive (ﬁrst-
episode) patients.
Our ﬁnding of reduced DLPFC as well as parietal function in
schizophrenia patients in the early phase of their illness is consistent
with most functional MRI studies in chronic patients (Callicott et al.,
2000; Manoach et al., 2000; Karlsgodt et al., 2007; Jansma et al., 2004;
Barch and Csernansky, 2007; Koch et al., 2008) and in early schizophre-
nia (Barch et al., 2001; Pantelis et al., 2007; Snitz et al., 2005) reporting
abnormal activation within DLPFC and within the functional cortical
networks involving the DLPFC, such as the fronto-parietal network.
The lack of effect of antipsychotic treatment on prefrontal lobe
function in our study is in linewith ﬁndings from a study of SchlagenhaufFig. 3. A. The effect of practice on brain activation (activation during the Novel task (NT) vers
healthy controls (HC) and schizophrenia patients (SZ) at the baseline scan and at the second
(p=0.007) and did not change over time. B. The effect of practice on brain activation in the D
but not included in the analysis. The effect of practice of non-responders was signiﬁcantly sm
at baseline was signiﬁcant smaller for non-responders compared to responders (p=0.03) an
practice on brain activation in the DLPFC and clinical improvement between baseline and sec
DLPFC was predictive of clinical outcome (p=0.005).* Even after excluding the patient th
(p=0.03). PANSS: positive and negative syndrome scale (Kay et al., 1987).et al. (2008) who reported no effects on frontal activation levels in
patients (n=10) compared to controls (n=10) 4 weeks after switching
from conventional drugs to olanzapine. Furthermore, our data are
consistent with a longitudinal fMRI study by Snitz et al. (2005), in
which controls and patients performed a task designed to probe DLPFC
and anterior cingulate cortex functioning. In this study medication-naive
patients (n=11)were rescannedafter4 weeksof treatmentwithatypical
antipsychotic medication. Interestingly, although treatment improved
functioning in the anterior cingulate cortex, it did not affect activity in the
DLPFC. The effect of retesting for controls however, was not explicitly
mentioned in this study.
There are a number of studies which do report normalization or
even an increase of activation levels due to neuroleptic medication.
For example, Honey et al. (1999) tested chronic schizophrenia
patients on a working memory task while they were on typical
antipsychotics, and 6 weeks later after having switched to risperi-
done. They reported increased activation in the right prefrontal
cortex, supplemental motor area, and the posterior parietal cortex.
Meisenzahl et al. (2006) found increased activation in the left
prefrontal cortex during a working memory task in 12 medication-
free patients after quetiapine treatment for 12 weeks. Finally, Wolf et
al. (2007) found increased activation in the frontotemporal cortex in
ten patients after treatment with atypical antipsychotics (including
clozapine) during 8 weeks. In these studies however, no repeat scan
was performed on healthy controls, which makes it impossible to
disentangle treatment effects from test–retest effects (Zandbelt et al.,
2008).us Practiced task (PT), in B-values) in the left dorsolateral prefrontal cortex (DLPFC) for
scan. The effect of practice in the DLPFCwas signiﬁcant smaller in schizophrenia patients
LPFC for responders, and non-responders. Data from the controls is added as a reference,
aller than for responders (p=0.002) and did not change over time. The effect of practice
d healthy controls (HC) (p=0.001). C. Scatter plot of the relation between the effect of
ond session (PANSS reduction in percent). The effect of practice on activation in the left
at had a substantial increase of symptoms over time, this effect remained signiﬁcant
161N.M.J. van Veelen et al. / Schizophrenia Research 129 (2011) 156–162Furthermore, although this is the ﬁrst study to report diminished
prefrontal lobe function in relation to poor treatment outcome in ﬁrst
episode patients using fMRI, our ﬁndings are in agreement with those
of Wood et al. (2006). In this study, using Magnetic resonance
Spectroscopy, a reduction in the NAA/CR ratio (a measure to indicate
neural loss) in the left prefrontal cortex was found in patients
showing poor functional outcome after 18 months of treatment. In
addition, McIntosh et al. (2010) found greater prefrontal tissue loss in
high-risk subjects who became unwell compared to those who did
not. These ﬁndings supports the idea that the group of patients with
reduced prefrontal lobe function (non-responders) may be charac-
terized by progressive (frontal) brain loss, a phenomenon that has
been associated with poor outcome in several longitudinal neuroim-
aging studies in schizophrenia (DeLisi et al., 2004; van Haren et al.,
2007; van Haren et al., 2008).
The present study has several limitations which should be
considered. Clinical outcome in the current study was measured
after 10 weeks of treatment, which may be regarded as a relatively
short period. It is however unlikely that non-responding patients
would respond to the same drug after a more prolonged treatment
period (Leucht et al., 2007; Emsley et al., 2006), as recent studies show
that longer term treatment response is already evident after 2 weeks
of treatment (Kinon et al., 2008). Therefore, our results may be
extrapolated to longer term outcome of ﬁrst episode schizophrenia
patients. Furthermore, only male patients participated in the study.
Therefore, the generalizability of our results across gender is limited,
since symptomatology and course of the disease are more favorable in
females as compared to males (Leung and Chue, 2000). Finally, our
ﬁnding that there were no intersession differences over groups should
be interpreted with caution, as the various atypical antipsychotics
prescribed may have a differential effect, and because test–retest
reproducibility of fMRI may be poor (Gradin et al., 2010; Gountouna
et al., 2010; Suckling et al., 2010; Raemaekers et al., 2007). As such,
our results should be taken as preliminary and should be replicated in
larger samples.
In conclusion, dysfunction of the DLPFC was present in ﬁrst-
episode medication-naive schizophrenia patients and was not
affected by subsequent antipsychotic treatment. Furthermore, dys-
function of the DLPFC at baseline was predictive of treatment
response, with patients showing a reduced beneﬁt of practice on
activation levels in the DLPFC at baseline. Our ﬁndings may be both
theoretically and clinically relevant. They support the notion that
prefrontal lobe dysfunction is not a unitary concept in schizophrenia
(Wood et al., 2006), explaining some of the inconsistent ﬁndings on
prefrontal lobe function in this illness. Our data suggest that
prefrontal lobe dysfunction may reﬂect a distinct neuropathological
substrate in a subgroup of schizophrenia patients who are clinically
characterized by non-response to treatment with dopamine antago-
nists. Subsequent genetic and neuroimaging studies should further
characterize this group of patients unraveling some of the diverse
neuropathological causes of schizophrenia.Role of funding source
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